Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.

Published on Jan 1, 2021in Cancer Immunology, Immunotherapy5.442
· DOI :10.1007/S00262-020-02663-Z
Yuli Guzman-Prado3
Estimated H-index: 3
Jennifer Ben Shimol2
Estimated H-index: 2
(TAU: Tel Aviv University),
Ondrej Samson3
Estimated H-index: 3
BACKGROUND As a result of the growing use of immune checkpoint inhibitors (ICIs) for treating malignancy, immune-related adverse events (irAEs) have been increasingly reported. Higher body mass index (BMI) has been highlighted as a potential risk factor for the development of irAEs. However, there are no meta-analyses summarizing the association between BMI and irAEs in patients on ICI therapies. METHODS PubMed, MEDLINE, EMBASE, Cochrane and grey literature were searched up to January 2020. Odds ratios (ORs) 95% and confidence intervals (CIs) were summarized using the random-effects model. Heterogeneity test, subgroup and sensitivity analyses were conducted. The protocol was registered on PROSPERO (number registration: CRD42020168790). RESULTS Five studies (n = 1937) met eligibility criteria for inclusion. Being overweight or obese was associated with an increased odds of developing irAEs (OR 2.62, 95% CI 1.70-4.03, P ≤ 0.00001, I2 = 53%). In subgroup analyses, higher BMI was associated with irAEs in patients using anti-CTLA-4 single agents or in combination with anti-PD-1/PD-L1 (OR 1.87, 95% CI 1.17-2.98, P = 0.009, I2 = 0%) and in patients using anti-PD-1/PD-L1 (OR 3.22, 95% CI 2.06-5.01, P = 0.00001, I2 = 32%) monotherapy. The increased odds of irAEs in patients with higher BMI was comparable (test for subgroup differences, P = 0.72, I2 = 0%) between studies with adjusted OR (OR 2.21, 95% CI 1.44-3.38, P = 0.0003, I2 = 4%) and unadjusted OR (OR 2.65, 95% CI 1.08-6.50, P = 0.03, I2 = 66%). CONCLUSION Our meta-analysis provides evidence of a relationship between higher BMI (overweight-obesity) and increased risk of irAEs in patients on ICI therapies. Further research is needed to strengthen this association.
📖 Papers frequently viewed together
201924.80JAMA Oncology
19 Authors (Yucai Wang, ..., Michael Wang)
210 Citations
8 Authors (Xiangyi Kong, ..., Jing Wang)
6 Citations
#1Ganessan Kichenadasse (Flinders University)H-Index: 3
#2John O. Miners (Flinders University)H-Index: 84
Last. Michael J. Sorich (Flinders University)H-Index: 4
view all 6 authors...
Importance High body mass index (BMI) is independently associated with overall survival benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether BMI is associated with outcomes in patients with advanced non–small cell lung cancer treated with atezolizumab remains unknown. Objective To examine whether BMI is associated with survival outcomes and adverse events in patients with non–small cell lung cancer (NSCLC) treated with atezolizumab. Design, Setting, and Partici...
64 CitationsSource
#1Omar Ali (UZH: University of Zurich)H-Index: 16
#1Omar Hasan Ali (Kantonsspital St. Gallen)H-Index: 9
Last. Lukas FlatzH-Index: 25
view all 17 authors...
Abstract Background Anti-PD1/PD-L1 therapy frequently entails immune-related adverse events (irAEs) and biomarkers to predict irAEs are lacking. While checkpoint inhibitors have been found to re-invigorate T-cells, the relevance of autoantibodies remains elusive. Objective Our aim was to explore whether IgG autoantibodies directed against co-expressed antigens by tumor tissue and healthy skin correlate with skin irAEs and therapy outcome. Methods We measured skin-specific IgG via ELISA in non-sm...
15 CitationsSource
#1Dominik Marschner (University of Freiburg)H-Index: 1
#2Martina Falk (University of Freiburg)H-Index: 2
Last. Natalie Köhler (Stanford University)H-Index: 3
view all 20 authors...
Immune checkpoint inhibitor (ICI) therapy has shown a significant benefit in the treatment of a variety of cancer entities. However, immune-related adverse events (irAEs) occur frequently and can lead to ICI treatment termination. MicroRNA-146a (miR-146a) has regulatory functions in immune cells. We observed that mice lacking miR-146a developed significantly more severe irAEs compared to wildtype mice in several irAE target organs in two different murine models. MiR-146a-/- mice exhibited increa...
10 CitationsSource
#1Laure HirschH-Index: 6
#2Audrey BellesoeurH-Index: 9
Last. François Goldwasser (Paris V: Paris Descartes University)H-Index: 62
view all 14 authors...
Abstract Background The occurrence of severe, acute limiting toxicity in patients receiving anti–programmed cell death receptor-1 monoclonal antibodies, such as nivolumab, is largely unpredictable. Sarcopenia was found to be associated with anti-cytotoxic T-lymphocyte-associated protein 4 acute toxicity. We explore the clinical and pharmacological parameters influencing nivolumab toxicity, including body composition. Methods From June 2015 to January 2017, all consecutive patients treated with n...
10 CitationsSource
#1Douglas Donnelly (NYU: New York University)H-Index: 5
#2Shirin Bajaj (NYU: New York University)H-Index: 3
Last. Judy ZhongH-Index: 17
view all 9 authors...
Despite major improvements in combatting metastatic melanoma since the advent of immunotherapy, the overall survival for patients with advanced disease remains low. Recently, there is a growing number of reports supporting an “obesity paradox,” in which patients who are overweight or mildly obese may exhibit a survival benefit in patients who received immune checkpoint inhibitors. We studied the relationship between body mass index and progression-free survival and overall survival in a cohort o...
29 CitationsSource
#1Yeonghee Eun (SMC: Samsung Medical Center)H-Index: 2
#2In Young KimH-Index: 9
Last. Jaejoon Lee (SMC: Samsung Medical Center)H-Index: 18
view all 8 authors...
We investigated risk factors for immune-related adverse events (irAEs) in patients treated with anti-programmed cell death protein1 antibody pembrolizumab. A retrospective medical record review was performed to identify all patients who received at least one dose of pembrolizumab at Samsung Medical Center, Seoul, Korea between June 2015 and December 2017. Three hundred and ninety-one patients were included in the study. Data were collected on baseline characteristics, treatment details, and adve...
33 CitationsSource
#1Adviti Naik (Khalifa University)H-Index: 8
#2Arta M. Monjazeb (UC Davis: University of California, Davis)H-Index: 26
Last. Julie Decock (Khalifa University)H-Index: 19
view all 3 authors...
Cancer immunotherapy has been heralded as a breakthrough cancer treatment demonstrating tremendous success in improving tumor responses and survival of patients with hematological cancers and solid tumors. This novel promising treatment approach has in particular triggered optimism for triple negative breast cancer (TNBC) treatment, a subtype of breast cancer with distinct clinical features and poor clinical outcome. In early 2019, the FDA granted the first approval of immune checkpoint therapy,...
17 CitationsSource
#1Meghan J. Mooradian (Harvard University)H-Index: 16
#2Mazen Nasrallah (Harvard University)H-Index: 3
Last. Sara R. Schoenfeld (Harvard University)H-Index: 9
view all 10 authors...
Abstract Background The use of immune checkpoint inhibition (ICI) has revolutionized cancer treatment. However, these medications are associated with significant and potentially debilitating immune-related adverse events (irAEs). While certain toxicities have been well studied, rheumatic complications have been less widely recognized and characterized. Methods We report our experience of patients who were evaluated by rheumatology after the development of a suspected rheumatic irAE following ICI...
33 CitationsSource
#1Alyson Haslam (OHSU: Oregon Health & Science University)H-Index: 9
#2Vinay PrasadH-Index: 38
Importance Immunotherapy checkpoint inhibitors have generated considerable interest because of durable responses in a number of hitherto intractable tumor types. Objective To estimate the percentage of patients with cancer in the United States who are eligible for and respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and Drug Administration (FDA). Design, Setting, and Participants Retrospective cross-sectional study performed from June 2018 through October 20...
274 CitationsSource
#1Fei Zhu (Soochow University (Suzhou))H-Index: 7
#2Fei Ye (Soochow University (Suzhou))H-Index: 1
Last. Bairong Shen (Sichuan University)H-Index: 31
view all 5 authors...
Heart disease is a malignant threat to human health. Electrocardiogram (ECG) tests are used to help diagnose heart disease by recording the heart’s activity. However, automated medical-aided diagnosis with computers usually requires a large volume of labeled clinical data without patients' privacy to train the model, which is an empirical problem that still needs to be solved. To address this problem, we propose a generative adversarial network (GAN), which is composed of a bidirectional long sh...
323 CitationsSource
Cited By8
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Tessa E H Römkens (Bosch)H-Index: 13
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 8 authors...
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients ...
#1Julie R. Brahmer (Johns Hopkins University)H-Index: 91
#2Hamzah Abu-Sbeih (UMKC: University of Missouri–Kansas City)H-Index: 3
Last. Douglas B. Johnson (Vandy: Vanderbilt University)H-Index: 70
view all 23 authors...
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guidel...
1 CitationsSource
#1Soravis Osataphan (Harvard University)H-Index: 3
Last. Charupong Saengboonmee (KKU: Khon Kaen University)H-Index: 5
view all 3 authors...
Cholangiocarcinoma (CCA) is a malignancy of bile duct epithelium, and its incidence is increasing globally. Numerous factors are reported associated with an increased risk of CCA and vary among populations across different areas. Obesity is a major, worldwide public health problem that leads to several complications and is associated with increased cancer risk. Although several epidemiological studies have shown that obesity is likely associated with the increased risk of CCA, this association m...
#2Lidia DelrieuH-Index: 3
Last. Pierre HeudelH-Index: 7
view all 9 authors...
The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Leon Berard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung can...
view all 6 authors...
Background Treatment with anti-PD-(L)1 antibodies, approved for several oncology indications, can lead to immune-related adverse events (irAEs). We aimed to investigate risk factors associated with an increased reporting of irAEs in patients treated with PD-(L)1 inhibitors approved for solid tumor indications. Patients and methods A retrospective review was performed of individual data from patients in phase II/III registrational studies for PD-(L)1 inhibitors in solid tumors. Data on baseline c...
#1Giuseppe AprileH-Index: 38
#2Debora BasileH-Index: 13
Last. Silvia StragliottoH-Index: 5
view all 9 authors...
Malnutrition and muscle wasting are frequently reported in cancer patients, either linked to the tumor itself or caused by oncologic therapies. Understanding the value of nutritional care during cancer treatment remains crucial. In fact, cancer-associated sarcopenia plays a key role in determining higher rates of morbidity, mortality, treatment-induced toxicities, prolonged hospitalizations and reduced adherence to anticancer treatment, worsening quality of life and survival. Planning baseline s...
1 CitationsSource
#1Y. Di Filippo (French Institute of Health and Medical Research)
#2Stéphane DalleH-Index: 57
Last. Henri Montaudié (French Institute of Health and Medical Research)H-Index: 17
view all 26 authors...
Background The “obesity paradox” suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events. This study assesses whether body mass index is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy. Patients and methods This m...
1 CitationsSource
#1Yuli Guzman-PradoH-Index: 3
#2Jennifer Ben Shimol (TAU: Tel Aviv University)H-Index: 2
Last. Ondrej SamsonH-Index: 3
view all 3 authors...
BACKGROUND Sarcopenia has been associated with negative clinical outcomes in cancer patients, particularly response to treatment and survival. The exponential growth in the use of immune checkpoint inhibitors (ICIs) has led to an increase in the reporting of both adverse events in general (AEs) and immune-related adverse events (irAEs), which are unintended immune-related phenomenon that take place as a result of checkpoint blockade. However, there are no systematic reviews evaluating the relati...
1 CitationsSource